Cara Therapeutics, Inc. (CARA)
| Previous close | 15.60 |
| Open | 15.50 |
| Bid | 15.35 x 900 |
| Ask | 15.78 x 800 |
| Day's range | 15.28 - 15.70 |
| 52-week range | 11.22 - 29.65 |
| Volume | 427,146 |
| Avg. volume | 1,552,188 |
| Market cap | 782.15M |
| Beta (5Y monthly) | 1.31 |
| PE ratio (TTM) | 88.31 |
| EPS (TTM) | 0.18 |
| Earnings date | 10 May 2021 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 26.33 |
- Motley Fool
Is Cara Therapeutics Stock a Buy After Its First FDA Drug Approval
Cara Therapeutics (NASDAQ: CARA) recently scored a key win with Food and Drug Administration approval of Korsuva in treating pruritis associated with chronic kidney disease for patients on hemodialysis. In this Motley Fool Live video recorded on Aug. 25, 2021, Motley Fool contributors Keith Speights and Brian Orelli discuss whether or not Cara stock is a buy after the big news. Another biotech had some good news on the FDA front: Cara Therapeutics, ticker there is CARA, and its partner Vifor Pharma (OTC: GNHAY) announced on Monday that the FDA had approved Korsuva for trading moderate to severe pruritus associated with chronic kidney disease, and this is in adults undergoing dialysis.
- Motley Fool
Why Cara Therapeutics Shot Higher Today
Cara Therapeutics (NASDAQ: CARA) was a hot stock on Tuesday. One of the formerly clinical-stage biotech's drug candidates won FDA approval, and investors reacted in the usual manner. The biotech company's most promising drug, Korsuva --- developed with Switzerland-based Vifor Pharma -- addresses this medical challenge sufficiently to win that all-important FDA approval.
- Zacks
CARA Drug Wins FDA Nod for Pruritus Associated With CKD
CARA gets a significant boost with FDA approval for Korsuva injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease in adults undergoing hemodialysis.
